| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
|
N Engl J Med
|
2011
|
11.01
|
|
2
|
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.
|
J Clin Invest
|
2008
|
7.05
|
|
3
|
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
|
J Clin Oncol
|
2010
|
5.20
|
|
4
|
Assessment of Minimal Residual Disease in Standard-Risk AML.
|
N Engl J Med
|
2016
|
5.07
|
|
5
|
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation.
|
Lancet
|
2005
|
4.09
|
|
6
|
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.
|
Blood
|
2005
|
3.68
|
|
7
|
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.
|
Blood
|
2007
|
3.18
|
|
8
|
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
|
Blood
|
2002
|
2.96
|
|
9
|
Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study.
|
J Natl Cancer Inst
|
2007
|
2.65
|
|
10
|
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen.
|
Blood
|
2002
|
2.56
|
|
11
|
T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma.
|
J Clin Oncol
|
2010
|
2.03
|
|
12
|
Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma.
|
J Clin Oncol
|
2011
|
2.01
|
|
13
|
In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.
|
Blood
|
2009
|
1.90
|
|
14
|
RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.
|
Blood
|
2005
|
1.85
|
|
15
|
Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia.
|
Blood
|
2006
|
1.80
|
|
16
|
Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National Cohort Study.
|
J Clin Oncol
|
2012
|
1.77
|
|
17
|
WT1 mutations in T-ALL.
|
Blood
|
2009
|
1.75
|
|
18
|
Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma.
|
Blood
|
2010
|
1.74
|
|
19
|
Constitutive activation of the Wnt/beta-catenin signalling pathway in acute myeloid leukaemia.
|
Oncogene
|
2005
|
1.70
|
|
20
|
Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.
|
Blood
|
2005
|
1.70
|
|
21
|
Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses.
|
Blood
|
2003
|
1.70
|
|
22
|
Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
|
J Clin Oncol
|
2012
|
1.66
|
|
23
|
Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2008
|
1.64
|
|
24
|
The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.
|
Blood
|
2011
|
1.62
|
|
25
|
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.
|
Blood
|
2002
|
1.59
|
|
26
|
Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia.
|
Genes Chromosomes Cancer
|
2008
|
1.55
|
|
27
|
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.
|
Blood
|
2007
|
1.54
|
|
28
|
Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.
|
Blood
|
2002
|
1.46
|
|
29
|
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
|
J Clin Oncol
|
2010
|
1.45
|
|
30
|
Treatment for lymph node tuberculosis.
|
BMJ
|
2010
|
1.45
|
|
31
|
Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia.
|
Clin Cancer Res
|
2007
|
1.44
|
|
32
|
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
|
Br J Haematol
|
2007
|
1.39
|
|
33
|
Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study.
|
J Clin Oncol
|
2011
|
1.30
|
|
34
|
High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2008
|
1.26
|
|
35
|
Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study.
|
J Clin Oncol
|
2006
|
1.24
|
|
36
|
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
|
J Clin Oncol
|
2009
|
1.22
|
|
37
|
The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status.
|
Blood
|
2010
|
1.22
|
|
38
|
An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia.
|
Oncogene
|
2002
|
1.22
|
|
39
|
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
|
J Clin Oncol
|
2002
|
1.22
|
|
40
|
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
|
Blood
|
2009
|
1.16
|
|
41
|
Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.
|
Br J Haematol
|
2006
|
1.10
|
|
42
|
G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction.
|
Glycobiology
|
2011
|
1.08
|
|
43
|
Does BCR/ABL1 positive acute myeloid leukaemia exist?
|
Br J Haematol
|
2013
|
1.08
|
|
44
|
Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD/SCID model.
|
Blood
|
2003
|
1.04
|
|
45
|
Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
|
Br J Haematol
|
2005
|
0.99
|
|
46
|
Long-term follow-up of granulocyte colony-stimulating factor receptor mutations in patients with severe congenital neutropenia: implications for leukaemogenesis and therapy.
|
Br J Haematol
|
2003
|
0.99
|
|
47
|
Paternal mosaicism proves the pathogenic nature of mutations in neutrophil elastase in severe congenital neutropenia.
|
Blood
|
2002
|
0.99
|
|
48
|
Homozygous HAX1 mutations in severe congenital neutropenia patients with sporadic disease: a novel mutation in two unrelated British kindreds.
|
Br J Haematol
|
2008
|
0.99
|
|
49
|
Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab.
|
Biol Blood Marrow Transplant
|
2004
|
0.98
|
|
50
|
Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used.
|
Br J Haematol
|
2006
|
0.98
|
|
51
|
Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7.
|
Genes Chromosomes Cancer
|
2002
|
0.97
|
|
52
|
Flt3 mutations and leukaemia.
|
Br J Haematol
|
2003
|
0.96
|
|
53
|
Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
|
Br J Haematol
|
2010
|
0.95
|
|
54
|
Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years.
|
Blood
|
2006
|
0.94
|
|
55
|
Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
|
Br J Haematol
|
2002
|
0.94
|
|
56
|
Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease.
|
Blood
|
2008
|
0.94
|
|
57
|
The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells.
|
Cancer Res
|
2002
|
0.92
|
|
58
|
Phenotypic heterogeneity and evidence of a founder effect associated with G6PC3 mutations in patients with severe congenital neutropenia.
|
Br J Haematol
|
2012
|
0.89
|
|
59
|
Different levels of p38 MAP kinase activity mediate distinct biological effects in primary human erythroid progenitors.
|
Br J Haematol
|
2003
|
0.88
|
|
60
|
Treatment of the elderly patient with diffuse large B cell lymphoma.
|
Br J Haematol
|
2012
|
0.87
|
|
61
|
Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning.
|
Br J Haematol
|
2013
|
0.86
|
|
62
|
PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
|
Br J Haematol
|
2014
|
0.86
|
|
63
|
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
|
Biol Blood Marrow Transplant
|
2003
|
0.86
|
|
64
|
Neutrophil elastase mutations in congenital neutropenia.
|
Hematology
|
2003
|
0.85
|
|
65
|
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
|
Br J Haematol
|
2012
|
0.85
|
|
66
|
GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
|
Br J Haematol
|
2013
|
0.84
|
|
67
|
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.
|
Br J Haematol
|
2008
|
0.84
|
|
68
|
Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma.
|
Br J Haematol
|
2013
|
0.84
|
|
69
|
Engraftment defect of cytokine-cultured adult human mobilized CD34(+) cells is related to reduced adhesion to bone marrow niche elements.
|
Br J Haematol
|
2012
|
0.84
|
|
70
|
Most acute myeloid leukaemia patients with intermediate mutant FLT3/ITD levels do not have detectable bi-allelic disease, indicating that heterozygous disease alone is associated with an adverse outcome.
|
Br J Haematol
|
2008
|
0.83
|
|
71
|
Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia.
|
Leuk Lymphoma
|
2003
|
0.82
|
|
72
|
HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning.
|
Blood
|
2010
|
0.82
|
|
73
|
Influence of cell cycling and cell division on transendothelial migration of CD34+ cells.
|
Br J Haematol
|
2002
|
0.81
|
|
74
|
Fetal haemopoietic cells display enhanced migration across endothelium.
|
Br J Haematol
|
2002
|
0.80
|
|
75
|
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
|
J Clin Oncol
|
2013
|
0.80
|
|
76
|
A review of gene therapy for haematological disorders.
|
Br J Haematol
|
2005
|
0.80
|
|
77
|
ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.
|
Leuk Lymphoma
|
2013
|
0.79
|
|
78
|
The production of JAK2 wild-type platelets is not downregulated in patients with JAK2 V617F mutant-positive essential thrombocythaemia.
|
Br J Haematol
|
2009
|
0.79
|
|
79
|
The role of allogeneic transplantation in non-Hodgkin's lymphoma.
|
Br J Haematol
|
2005
|
0.79
|
|
80
|
Variable product purity and functional capacity after CD34 selection: a direct comparison of the CliniMACS (v2.1) and Isolex 300i (v2.5) clinical scale devices.
|
Br J Haematol
|
2002
|
0.79
|
|
81
|
Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
|
Br J Haematol
|
2011
|
0.78
|
|
82
|
The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study.
|
Hematology
|
2008
|
0.77
|
|
83
|
Incidence and prognostic significance of C-MPL expression in acute myeloid leukemia.
|
Leuk Res
|
2003
|
0.77
|
|
84
|
Lack of effect of the human GM-CSF analog E21R on the survival of primary human acute myeloid leukemia cells.
|
Blood
|
2003
|
0.77
|
|
85
|
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result in durable remissions, irrespective of prior rituximab exposure.
|
Br J Haematol
|
2014
|
0.77
|
|
86
|
Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen.
|
Blood
|
2002
|
0.75
|
|
87
|
Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma.
|
Anticancer Drugs
|
2002
|
0.75
|
|
88
|
Re-infused lymphocyte dose does not influence disease control following upfront autologous stem cell transplantation for multiple myeloma.
|
Br J Haematol
|
2012
|
0.75
|
|
89
|
[Therapy of lymph node tuberculosis].
|
Praxis (Bern 1994)
|
2010
|
0.75
|
|
90
|
No mutations in the GATA-1 gene detected in patients with acquired essential thrombocythemia.
|
Haematologica
|
2004
|
0.75
|
|
91
|
Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy.
|
J Geriatr Oncol
|
2013
|
0.75
|